Claims

- 1. A composition for treating or preventing a flavivirus or pestivirus infection, comprising a Jabl (Junactivation binding protein 1) protein.
- 2. The composition as set forth in claim 1, wherein the Jabl protein has an amino acid sequence designated as SEQ ID No. 2.
- 3. The composition as set forth in claim 1, wherein the Jabl protein is encoded by a nucleotide sequence designated as SEQ ID No. 1.
 - 4. A composition for treating or preventing a flavivirus or pestivirus infection, comprising a nucleic acid having a nucleotide sequence coding for a Jabl protein.
- 5. The composition as set forth in claim 4, wherein the nucleic acid having the nucleotide sequence coding for the Jabl protein is a recombinant vector having a nucleotide sequence coding for an amino acid sequence designated as SEQ ID No. 2.
- 20 6. The composition as set forth in claim 4, wherein

the nucleic acid having the nucleotide sequence coding for the Jabl protein is a recombinant vector having a nucleotide sequence designated as SEQ ID No. 1.

- 7. The composition as set forth in claim 5 or 6,
 wherein the recombinant vector is a recombinant viral vector.
 - 8. The composition as set forth in claim 7, wherein the recombinant viral vector is selected from among recombinant retrovirus, adenovirus, adeno-associated virus and herpes simplex virus.

10

- 9. A composition for treating or preventing a flavivirus or pestivirus infection, comprising a recombinant virus expressing a Jabl protein.
- 10. The composition as set forth in claim 9, wherein
 the recombinant vector expressing the Jabl protein is a
 recombinant virus expressing a Jabl protein having an amino
 acid sequence designated as SEQ ID No. 2.
- 11. The composition as set forth in claim 9, wherein the recombinant vector expressing the Jabl protein is a recombinant virus expressing a Jabl protein encoded by a nucleotide sequence designated as SEQ ID No. 1.

- 12. The composition as set forth in claim 9, wherein the recombinant vector is selected from among adenovirus, adeno-associated virus and herpes simplex virus.
- 13. The composition as set forth in claim 12, wherein the recombinant vector is selected from among retrovirus and adenovirus.
 - 14. The composition as set forth in any one of claims 1, 4 and 9, wherein the infection is a flavivirus infection.
- 15. The composition as set forth in claim 14, wherein the flavivirus is West Nile virus.

15

- 16. The composition as set forth in any one of claims 1, 4 and 9, wherein the infection is associated with fever, rash, bleeding, jaundice, arthralgia, myalgia, encephalitis or meningitis.
- 17. A method of screening a compound stimulating expression of a Jabl protein, comprising:
 - (a) culturing a cell expressing the Jab1 protein;
- (b) contacting the cell cultured at (a) with candidate compounds for stimulating expression of

the Jabl protein;

15

- (c) comparing an expression level of the Jabl protein at (b) with that in a control not contacted with the candidate compounds; and
- 5 (d) identifying a compound increasing expression levels of the Jabl protein.
 - 18. A method of screening a compound stimulating interaction between a Jabl protein and a capsid (Cp) protein, comprising:
- 10 (a) culturing a cell transformed with both a recombinant vector expressing the Jabl protein and another recombinant vector expressing the Cp protein of flavivirus or pestivirus;
 - (b) contacting the cell cultured at (a) with candidate compounds for stimulating interaction between the Jabl protein and the Cp protein;
 - (c) comparing an expression level of the Cp protein at(b) with that in a control not contacted with the candidate compounds; and
- 20 (d) identifying a compound reducing expression levels of the Cp protein.
 - 19. The method as set forth in claim 17 or 18, wherein the comparison of expression levels at (c) is carried out in protein or mRNA levels.

- 20. The method as set forth in claim 19, wherein the comparison of expression levels is carried out by an immunoassay method.
- 21. The method as set forth in claim 19, wherein the comparison of expression levels is carried out in mRNA levels by RT-PCT (Reverse Transcription-Polymerization Chain Reaction).